Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes

References

• Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Inf Dis 2004; 39:1642-50; http://dx.doi.org/10.1086/425615
   PubMed Web of Science ®Google Scholar
• Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012; 21:57-65; PMID:22379175; http://dx.doi.org/10.1183/09059180.00008911
   PubMedGoogle Scholar
• van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849-59; PMID:15509818; http://dx.doi.org/10.1056/NEJMoa040845
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 2014; 32:2399-405; PMID:24637174; http://dx.doi.org/10.1016/j.vaccine.2014.02.096
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1-24.
   PubMedGoogle Scholar
• Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60; PMID:1944423; http://dx.doi.org/10.1056/NEJM199111213252101
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 1993; 270:1826-31; PMID:8411526; http://dx.doi.org/10.1001/jama.1993.03510150060030
   PubMed Web of Science ®Google Scholar
• Fedson DS, Shapiro ED, LaForce FM, Mufson MA, Musher DM, Spika JS, Breiman RF, Broome CV. Pneumococcal vaccine after 15 years of use: another view. Arch Intern Med 1994; 154:2531-5; PMID:7979849
   PubMedGoogle Scholar
• Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D'Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340:c1004; PMID:20211953; http://dx.doi.org/10.1136/bmj.c1004
   PubMed Web of Science ®Google Scholar
• Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108:653-7; PMID:3358567; http://dx.doi.org/10.7326/0003-4819-108-5-653
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101:325-30; PMID:6380367; http://dx.doi.org/10.7326/0003-4819-101-3-325
   PubMed Web of Science ®Google Scholar
• Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, Anglim AM. Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch Intern Med 1995; 155:2336-40; PMID:7487259; http://dx.doi.org/10.1001/archinte.1995.00430210086013
   PubMed Web of Science ®Google Scholar
• Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, Mäkelä PH, Broome CV, Facklam RR, Tiesjema RH, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148:1136-59; PMID:6361173; http://dx.doi.org/10.1093/infdis/148.6.1136
   PubMed Web of Science ®Google Scholar
• Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238:2613-6; PMID:21973; http://dx.doi.org/10.1001/jama.1977.03280250039019
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, Krogfelt KA, Konradsen HB, Benfield TL. Pneumococcal serotypes and mortality following invasive pneumococcal disease: A population-based cohort study. PLoS Med 2009; 6:e1000081; PMID:19468297; http://dx.doi.org/10.1371/journal.pmed.1000081
   PubMed Web of Science ®Google Scholar
• Sankilampi U, Herva E, Haikala R, Liimatainen O, Renkonen OV, Leinonen M. Epidemiology of invasive Streptococcus pneumoniae infections in adults in Finland. Epidemiol Infect 1997; 118:7-15; PMID:9042030; http://dx.doi.org/10.1017/S0950268896007169
   PubMed Web of Science ®Google Scholar
• Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E. Invasive pneumococcal disease among adults: Associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49:e23-9; PMID:19522653; http://dx.doi.org/10.1086/600045
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043
   PubMed Web of Science ®Google Scholar
• Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011. Vaccine 2013; 31:5863-71; PMID:24099873; http://dx.doi.org/10.1016/j.vaccine.2013.09.049
   PubMed Web of Science ®Google Scholar
• Sjöström K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kühlmann-Berenzon S, Henriques-Normark B. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006; 42:451-9; PMID:16421787; http://dx.doi.org/10.1086/499242
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, George R, Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: Coverage of different vaccines and insight into non-vaccine serotypes. PLoS One 2012; 7:e39150; PMID:22815698; http://dx.doi.org/10.1371/journal.pone.0039150
   PubMed Web of Science ®Google Scholar
• Mair S, Fiquet A, Meghlaoui G, Thomas S, Ledesma E. Immunogenicity and safety of PNEUMOVAX II manufactured by a new process in older adults. Hum Vaccin 2009; 5:608-13; PMID:19617717; http://dx.doi.org/10.4161/hv.9228
   PubMed Web of Science ®Google Scholar
• Demczuk WHB, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrel GJ, Desai S, Sherrard L, Adam H, et al. Serotype distribution of invasive Steptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012. Can J Microbiol 2013; 59:778-88; PMID:24313450; http://dx.doi.org/10.1139/cjm-2013-0614
   PubMed Web of Science ®Google Scholar
• Richter SS, Diekema Dj, Heilmann KP, Dohrn CL, Riahi F, Doern GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent pneumococcal conjugate vaccine in the United States. Antimicrobial Agents and Chemotherapy 2014; 58:6484-9; PMID:25136018; http://dx.doi.org/10.1128/AAC.03344-14
   PubMed Web of Science ®Google Scholar
• Johnson SE, Rubin L, Romero-Steiner S, Dykes JK, Pais LB, Rizvi A, Ades E, Carlone GM. Correlation of Opsonophagocytosis and Passive Protection Assays Using Human Anticapsular Antibodies in an Infant Mouse Model for Bacteremia for Streptococcus pneumoniae. J Infect Dis 1999; 180:133-40; PMID:10353871; http://dx.doi.org/10.1086/314845
   PubMed Web of Science ®Google Scholar
• Baxendale HE, Johnson M, Stephens RC, Yuste J, Klein N, Brown JS, Goldblatt D. Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin Exp Immunol 2008; 151:51-60; PMID:17983446; http://dx.doi.org/10.1111/j.1365-2249.2007.03535.x
   PubMed Web of Science ®Google Scholar
• Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25:3816-26; PMID:17368878; http://dx.doi.org/10.1016/j.vaccine.2007.01.119
   PubMed Web of Science ®Google Scholar
• Ekström N, Väkeväinen M, Verho J, Kilpi T, Käyhty H. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun 2007; 75:1794-800; PMID:17261612; http://dx.doi.org/10.1128/IAI.01673-06
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014; 14:839-46; PMID:25042756; http://dx.doi.org/10.1016/S1473-3099(14)70822-9
   PubMed Web of Science ®Google Scholar
• Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, Romero-Steiner S, Rajam G, Glass NE, Whitney CG, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged ≥65 years. J Infect Dis 2010; 201:525-33; PMID:20088694; http://dx.doi.org/10.1086/651131
   PubMed Web of Science ®Google Scholar
• Hechter RC, Chao C, Jacobsen SJ, Slezak JM, Quinn VP, Van Den Eeden SK, Tseng HF. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study. Vaccine 2012; 30:5625-30; PMID:22789510; http://dx.doi.org/10.1016/j.vaccine.2012.06.085
   PubMed Web of Science ®Google Scholar
• Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, Reid RD. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89:184-94; PMID:14433
   PubMedGoogle Scholar
• Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: Current status of polyvalent vaccines. J Infect Dis 1977; 136:S38-S42; PMID:19543; http://dx.doi.org/10.1093/infdis/136.Supplement.S38
   PubMedGoogle Scholar
• Riley ID, Tarr PI, Andrews M, Pfeiffer M, Howard R, Challands P, Jennison G. Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977; 1:1338-41; PMID:69058; http://dx.doi.org/10.1016/S0140-6736(77)92552-1
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009; 27:1504-10; PMID:19171174; http://dx.doi.org/10.1016/j.vaccine.2009.01.013
   PubMed Web of Science ®Google Scholar
• Örtqvist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, Lindblad I, Sundelöf B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351:399-403.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-55; PMID:12724480; http://dx.doi.org/10.1056/NEJMoa022678
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422.
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58; PMID:19124790; http://dx.doi.org/10.1503/cmaj.080734
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; 1:CD000422; PMID:18253977
   PubMed Web of Science ®Google Scholar
• Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3:71-8; PMID:12560191; http://dx.doi.org/10.1016/S1473-3099(03)00514-0
   PubMed Web of Science ®Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged >=60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014; 58:909-17; PMID:24532544; http://dx.doi.org/10.1093/cid/ciu002
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
   PubMed Web of Science ®Google Scholar
• Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the oxfordshire region of england. J Infect Dis 2014; 210:1001-11; PMID:24719477; http://dx.doi.org/10.1093/infdis/jiu213
   PubMed Web of Science ®Google Scholar
• Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012. Can J Microbiol 2013; 59:778-88; PMID:24313450; http://dx.doi.org/10.1139/cjm-2013-0614
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis 2014; 58:854-64; PMID:24344141; http://dx.doi.org/10.1093/cid/cit800
   PubMed Web of Science ®Google Scholar
• Marchese RD, Jain NT, Antonello J, Mallette L, Butterfield-Gerson KL, Raab J, Burke P, Schulman C, Adgate H, Sikkema DJ, et al. Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: Assay operating characteristics and correlation to the WHO International Assay. Clin Vaccine Immunol 2006; 13:905-12; PMID:16893991; http://dx.doi.org/10.1128/CVI.00014-06
   PubMed Web of Science ®Google Scholar